MIND Institute study of anxiety in children with ASD has now expanded to offer online treatment

It's now easier than ever to take part in a study that includes treatment for anxiety in children with autism spectrum disorder (ASD) at the UC Davis MIND Institute's Autism Center of Excellence.

Parents can get customized therapy for their child from the Institute's trained experts without leaving home. It's part of a clinical trial called the Specifying and Treating Anxiety in Autism Research, or STAAR Study. And it has now expanded to offer online, telehealth study treatment appointments.

It compares the effectiveness of two treatments in children ages 8-14: the medication sertraline and individualized cognitive behavioral therapy (CBT). CBT is a well-researched, problem-solving, goal-directed therapy that examines and treats the relationships between thoughts and behaviors that are maintaining the anxious feelings.

"Most of it can be done from your couch," said Marjorie Solomon, professor of psychiatry and behavioral sciences, who's leading the trial. Solomon, a MIND Institute faculty member, said that when COVID-19 forced the cancellation of in-person research appointments, she and her team saw an opportunity.

"The online model is really exciting because it can be delivered so much more broadly to people who don't live near the MIND Institute. We can serve people in Stockton, in Orange County and all over California. It really increases access," she said.

At least 50 percent of children with autism exhibit clinically significant anxiety symptoms.

If your child has anxiety, that has a negative impact on so many aspects of their life: academically, socially, eventually career-wise. Anxiety has a really profound effect on well-being, and children that are anxious aren't happy, so we really want to correct that."  

Marjorie Solomon, professor of psychiatry and behavioral sciences, UC Davis MIND Institute's Autism Center of Excellence

Medication vs. therapy

Children enrolled in STAAR will be randomly assigned to either receive the medication sertraline (or a placebo) or CBT for 16 weeks. They'll also be asked to get some lab work completed, which can be done at many locations throughout the state, as well as offered an optional MRI scan, which is done at the UC Davis Imaging Research Center in Sacramento. There is no cost to take part in the study.

Sertraline is an antidepressant, known as a selective serotonin reuptake inhibitor, and it may be used to help with symptoms of anxiety or autism. Some trial participants will take sertraline daily, and others will be given a placebo as a control.

Others will be assigned CBT. Participants and their parents will take part in 1.5-hour, interactive therapy sessions via a videoconferencing program on a tablet, phone or computer. The sessions will be administered by psychologists well-trained in CBT.

"Surprisingly, there aren't really any big studies of either CBT or sertraline in this population, and we are the first single study to compare the two," Solomon noted.

When their treatment in the study ends, participants in the placebo group are offered the option of either CBT or sertraline.

"It's state-of-the-art, comprehensive assessment and treatment, and now, you can do it from the safety of your own home - it's a great opportunity," said Solomon.

The MIND Institute is currently recruiting children with autism and anxiety, ages 8-14, to take part in the STAAR study. Information about STARR can be found here, or you can email [email protected] or call 916-703-0119.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cannabigerol shows promise in reducing anxiety and enhancing memory without side effects